Plasma homocysteine concentration and blood pressure in healthy Iranian adults: The Tehran homocysteine survey (2003-2004)

Journal of Human Hypertension

Volumn 19, Issue 11, 2005, Pages 869-876

  Fakhrzadeh, H ^a,c   Ghotbi, S ^a   Pourebrahim, R ^a   Heshmat, R ^b   Nouri, M ^a   Shafaee, A ^a   Larijani, B ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood pressure; Folate; Homocysteine; Hypertension; Risk factor; Vitamin B12

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGE; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEALTH SURVEY; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; IRAN; MALE; METHODOLOGY; POPULATION RESEARCH; QUANTITATIVE ANALYSIS; REST; RISK FACTOR; SEAT; STANDARDIZATION;

ADULT; BLOOD PRESSURE; FEMALE; HEALTH SURVEYS; HOMOCYSTEINE; HUMANS; HYPERTENSION; IRAN; MALE; MIDDLE AGED; RISK FACTORS; SAMPLING STUDIES;

EID: 27844534033     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001911     Document Type: Article

References (59)

1. Bortolotto LA et al. Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension 1999; 34: 837-842.
2. Carretero OA, Oparil S. Essential hypertension. Part I: Definition and aetiology. Circulation 2000; 101: 329-335.
3. Krauss RMAet al. AHA dietary guidelines: Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000; 102: 2284-2299.
4. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2002; 156: 1105-1113.
5. Nygard O et al. Total plasma homocysteine and cardiovascular risk profile: The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-1533.
6. Jacques PF et al. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001; 73: 613-621.
7. van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and blood pressure. Curr Hypertens Rep 2003; 5: 26-31.
8. Sundstrom J et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking. The Framingham Heart Study. Hypertension 2003; 42: 1100-1105.
9. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050.
10. Dinavahi R, Falkner B. Relationship of homocysteine with cardiovascular disease and blood pressure. J Clin Hypertens 2004; 6: 494-498.
11. Graham IM et al. Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 1997; 277: 1775-1781.
12. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury. Thromb Res 1980; 18: 113-121.
13. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteineinduced endothelial injury and arteriosclerosis in baboons. Circ Res 1983; 53: 731-739.
14. Outinen PA et al. Characterization of the stress-inducing effects of homocysteine. Biochem J 1998; 332: 213-221.
15. Upchurch GR et al. Homocysteine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-17017.
16. Chambers JC et al. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: An effect reversible with vitamin C therapy. Circulation 1999; 99: 1156-1160.
17. Nappo F et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 81: 2113-2118.
18. Woo KS et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-2544.
19. Tawakol A et al. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-1121.
20. Nygard O et al. Total homocysteine and cardiovascular disease. J Intern Med 1999; 246: 425-454.
21. 6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998; 5: 249-255.
22. 12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59: 940-948.
23. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279: 359-364.
24. Verhoef P et al. Homocysteine, vitamin status and risk of vascular disease: Effects of gender and menopausal status. Eur Heart J 1999; 20: 1115-1123.
25. Stroes E et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41-46.
26. Verhaar MC et al. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998; 97: 237-241.
27. Usui M et al. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci (Lond) 1999; 96: 235-239.
28. Stehouwer CD, van Guldener C. Does homocysteine cause hypertension? Clin Chem Lab Med 2003; 41: 1408-1411.
29. WHO MONICA Project. Geographical variation in the major risk factors of coronary heart disease in men and women aged 25-64 years. World Health Stat Q 1988; 41: 115-137.
30. WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): A major international collaboration. J Clin Epidemiol 1988; 41: 105-114.
31. Freidewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
32. Blood pressure levels. In: Heart and Stroke Encyclopedia: A-Z Guide, from the 7th Report of the JNC on detection, Evaluation, and Treatment of High Blood Pressure. American Heart Association: Dallas, TX, 2005 (http://www.americanheart.org/presenter.jhtml?identifier=4450).
33. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: Pathophysiology, screening, and treatment. Arch Intern Med 1998; 158: 1301-1306.
34. Selhub J et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999; 131: 331-339.
35. American Diabetes Association. Clinical practice recommendations 1997. Diabetes Care 1997; 20: S1-S70.
36. 12 in 25-64 aged Inhabitants of Tehran University of Medical Sciences Population Lab Region. Iranian J Diabetes Lipid Disorders 2004; 3(Suppl 1): (MONICA PROJECT): 99-109.
37. Horan MJ, Lenfant C. Epidemiology of blood pressure and predictors of hypertension. Hypertension 1990; 15: 20-24.
38. Boers GHJ. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost 2000; 26: 291-295.
39. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
40. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
41. Nygard O et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Eng J Med 1997; 274: 230-236.
42. Kahleova R et al. Essential hypertension in adolescents: Association with insulin resistance and with metabolism of homocysteine and vitamins. Am J Hypertens 2002; 15: 857-864.
43. Malinow MR et al. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis 1995; 114: 175-183.
44. Osganian SK et al. Distribution of and factors associated with serum homocysteine levels in children: Child and adolescent trial for cardiovascular health. JAMA 1999; 281: 1189-1196.
45. Hoogeveen EK et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in noninsulin-dependent diabetes mellitus: A population-based study. Arterioscler Thromb Vasc Biol 1998; 18: 133-138.
46. Sutton-Tyrrel K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997; 96: 1745-1749.
47. Sharabi Y et al. Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events. Am J Hypertens 1999; 12: 766-771.
48. Perry IJ. Homocysteine, hypertension and stroke. J Hum Hypertens 1999; 13: 289-293.
49. van Dijk RA et al. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: A 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 2001; 21: 2072-2079.
50. Bates CJ et al. Plasma total homocysteine in a representative sample of 972 British men and women aged 65 and over. Eur J Clin Nutr 1997; 51: 691-697.
51. 6, pyridoxal phosphate, and folate. Am J Cardiol 1995; 75: 1107-1111.
52. Brattstrom L et al. Hyperhomocysteinemia in stroke: Prevalence, cause, and relationship to type of stroke and stroke risk factors. Eur J Clin Invest 1992; 22: 214-221.
53. Zhan S et al. A case-control study on the relationship between abnormal homocysteine metabolism and essential hypertension. Zhonghua Liu Xing Bing Xue Za Zhi 2000; 21: 194-197.
54. Virdis A et al. Hyperhomocyst(e)inemia: Is this a novel risk factor in hypertension? J Nephrol 2002; 15: 414-421.
55. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr 2000; 72: 315-323.
56. Westphal S, Rading A, Luley C, Dierkes J. Antihypertensive treatment and homocysteine concentrations. Metabolism 2003; 52: 261-263.
57. Smith SC, Greenland P, Grundy SM. AHA Prevention Conference V.: Beyond secondary prevention: Identifying the high-risk patient for primary prevention. Executive summary. Circulation 2000; 101: 111-116.
58. Appel LJ et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-1124.
59. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: Causal or casual? Arch Intern Med 2000; 160: 422-434.